PTC Therapeutics

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

 
Press Releases
  Date Title and Summary View
Mar 14, 2016
SOUTH PLAINFIELD, N.J., March 14, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that data from the Phase 3, double-blind, placebo-controlled, 48-week ACT DMD trial of Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) will be presented at the 5th International Congres...
Mar 2, 2016
SOUTH PLAINFIELD, N.J., March 2, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on February 25, 2016 it approved non-statutory stock options to purchase an aggregate of 29,500 shares of its common stock to 12 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our ...
Feb 29, 2016
SOUTH PLAINFIELD, N.J., Feb. 29, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2015. "We are shocked and disappointed to have received a Refuse to File (RTF) letter from the FDA regarding our NDA for Transl...
Feb 26, 2016
SOUTH PLAINFIELD, N.J., Feb. 26, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company has had multiple discussions with the German Federal Association of the Statutory Health Insurances (GKV-SV) over the last several months to come to agreement on pricing and reimbursement.  Recently, these discussions transit...
Feb 23, 2016
SOUTH PLAINFIELD, N.J., Feb. 23, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it received yesterday evening a Refuse to File letter from the United States Food and Drug Administration (FDA) regarding PTC's New Drug Application (NDA) for Translarna™ (ataluren), an oral, first-in-class, protein restoration the...
Feb 15, 2016
SOUTH PLAINFIELD, N.J., Feb. 15, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and year end 2015 financial results and provide an update on the company's business and outlook on Monday, February 29, 2016 at 4:30 p.m. (ET) after the closing...
Feb 12, 2016
SOUTH PLAINFIELD, N.J., Feb. 12, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the second annual STRIVE (Strategies to Realize Innovation, Vision and Empowerment) grant award program for Duchenne muscular dystrophy (DMD). STRIVE provides funds to patient advocacy organizations to develop unique and collaborative program...
Jan 28, 2016
SOUTH PLAINFIELD, N.J., Jan. 28, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Leerink Partners' 5th Annual Global Healthcare Conference, on Thursday, February 11th at 1:25 p.m. ET RBC Capital Markets Global Healthcare Conference,...
Jan 11, 2016
SOUTH PLAINFIELD, N.J., Jan. 11, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided a corporate update, which will be detailed at the company's presentation at the 34th Annual J.P. Morgan Healthcare Conference. Stuart W. Peltz, Ph.D., Chief Executive Officer will present the company's corporate strategy and anticipated 2016 m...
Jan 8, 2016
SOUTH PLAINFIELD, N.J., Jan. 8, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the completion of its rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for Translarna™ (ataluren), an oral, first-in-class, protein restoration therapy for the treatment of nonsen...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue